Harvard Bioscience, Inc. HBIO
7.96
(0.06)
(0.75%)
as of 25 Sep
- Market cap
- $36.5M
- P/E
- 0.0×
Follow HBIO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (89.95%) | (78.65%) | (147.13%) | (135.62%) |
+8 more TTM periods Free account |
|
| (13.32%) | (12.41%) | (54.86%) | (51.46%) | ||
ROIC |
(0.41%) | (0.14%) | (74.07%) | (76.24%) | |
Return on Tangible Assets |
(38.54%) | (34.35%) | (182.60%) | 961.17% | |
Average Days of Receivables |
60.27 | 62.19 | 67.66 | 50.59 | |
Free Cash Flow per Share |
(0.40) | 0.29 | 1.10 | 1.53 | |
Free Cash Flow |
(1.83) | 1.28 | 4.87 | 6.82 | |
Capital Expenditures |
(2.48) | (1.80) | (1.86) | (1.73) | |
Piotroski F-Score |
6.00 | 6.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
1.29% | 5.77% | 11.56% | 15.59% | |
Accounts Receivable Turnover |
6.64 | 6.10 | 5.60 | 7.01 | |
Accounts Payable Turnover |
6.71 | 7.05 | 8.68 | 7.19 | |
Inventory Turnover |
1.65 | 1.58 | 1.66 | 1.58 | |
Average Days of Payables |
61.83 | 54.27 | 36.38 | 50.22 | |
Days of Inventory on Hand |
220.84 | 227.91 | 207.26 | 209.60 | |
Tax Rate |
(0.01) | (0.01) | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
10.36% | 10.32% | 10.20% | 10.27% | |
Selling, General and Administrative Expense of Revenue |
43.34% | 43.07% | 42.70% | 43.43% | |
Share Based Compensation of Revenue |
1.62% | 1.77% | 2.14% | 2.70% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.06) | (0.31) | (0.12) | (0.16) | |
Depreciation/Fixed assets |
1.37 | 1.49 | 11.54 | 11.04 | |
Capex/Depreciation |
(0.34) | (0.25) | (0.03) | (0.03) | |
Revenue per Share |
19.40 | 19.12 | 19.50 | 19.61 | |
Operating CF per Share |
0.14 | 0.69 | 1.52 | 1.92 | |
Capex per Share |
(0.55) | (0.40) | (0.42) | (0.39) | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
(11.86%) | (11.44%) | (65.51%) | (61.62%) |
Columns are period end dates